Sphere-9 Catheter Ablation for Atrial Fibrillation
(Conquer-AF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia.
Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.
Who Is on the Research Team?
Khaldoun Tarakji, MD
Principal Investigator
Medtronic
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Sphere-9 Catheter Ablation
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants undergo a redo atrial fibrillation ablation using the Sphere-9 Catheter and the Affera Ablation System per study protocol. All subjects receive the same intervention with no control or comparator arm.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medtronic Cardiac Ablation Solutions
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.